Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma

Afsar, Cıgdem; Karabulut, Mehmet; Karabulut, Senem; Alis, Halil; Gonenc, Murat; Dagoglu, Nergiz; Serilmez, Murat; Tas, Faruk

doi:10.1016/j.jiac.2016.12.003

Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma

Copy For Citation

Afsar C. U., Karabulut M., Karabulut S., Alis H., Gonenc M., Dagoglu N., ...More

JOURNAL OF INFECTION AND CHEMOTHERAPY, vol.23, pp.196-200, 2017 (SCI-Expanded)

Publication Type: Article / Article
Volume: 23
Publication Date: 2017
Doi Number: 10.1016/j.jiac.2016.12.003
Journal Name: JOURNAL OF INFECTION AND CHEMOTHERAPY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.196-200
Keywords: IL-18, Diagnostic, Pancreatic adenocarcinoma, Predictive, Serum, CANCER, METASTASIS, EXPRESSION
Istanbul University Affiliated: Yes

Abstract

Background: This study was conducted to investigate the serum levels of interleukin-18 (IL-18) in patients with pancreatic adenocarcinoma (PA) and the relationship with tumor progression and known prognostic parameters.